From Wikipedia, the free encyclopedia
Chemical compound
Nidufexor
4-{[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl}benzoic acid
CAS Number
PubChem
CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (
EPA )
Formula C 27 H 22 Cl N 3 O 4
Molar mass 487.94 g·mol−1 3D model (
JSmol )
CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O
InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)
Key:JYTIXGYXBIBOMN-UHFFFAOYSA-N
Nidufexor (LMB-763 ) is a drug which acts as a
partial agonist of the
farnesoid X receptor (FXR). It has reached Phase II
clinical trials for the treatment of
diabetic nephropathy and
nonalcoholic steatohepatitis .
[1]
[2]
See also
References
^ Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, et al. (April 2020).
"Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis" . Journal of Medicinal Chemistry . 63 (8): 3868–3880.
doi :
10.1021/acs.jmedchem.9b01621 .
PMID
31940200 .
^ Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E (June 2020). "Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)". Expert Opinion on Investigational Drugs . 29 (6): 623–632.
doi :
10.1080/13543784.2020.1763302 .
PMID
32552182 .
S2CID
219911969 .
FXR Tooltip Farnesoid X receptor
LXR Tooltip Liver X receptor